Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
All content for Beyond the Endpoint is the property of Duke Clinical Research Institute and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
The Intersection of Politics and Medicine: Impacts on Clinical Practice
Beyond the Endpoint
32 minutes 37 seconds
9 months ago
The Intersection of Politics and Medicine: Impacts on Clinical Practice
In this episode of Beyond the Endpoint, Emily O’Brien and Manesh Patel sit down with Leslie Curtis, former senior FDA policy advisor, to explore the FDA’s role in balancing science, public health, and regulation, along with how political transitions influence clinical research, healthcare funding, and the approval process for new treatments.
🔗 Access resources related to this episode https://dcri.org/blog/ep-3-intersection-politics-and-medicine-impacts-clinical-practice
Beyond the Endpoint
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
